Pharmaceutical

J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe

Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.

Oct 24, 2024 - 04:00
J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe
Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.
Read the original article

Tags:

Previous Article

Be Bio raises $82m to advance haemophilia B gene therapy to Phase I/II trial

Next Article

FDA expands Pfizer’s RSV vaccine label to include all high-risk adults

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biden to tap head of National Cancer Institute to lead NIH

STAT+: Biden to tap head of National Cancer Institute t...

Apr 23, 2023

Defender’s plans for motion sickness nasal gel stop with FDA rejection

Defender’s plans for motion sickness nasal gel stop wit...

Jan 31, 2024

Gene therapy death not caused by CRISPR, investigators confirm

Gene therapy death not caused by CRISPR, investigators ...

May 19, 2023